News | Antiplatelet and Anticoagulation Therapies | May 09, 2016

Anticoagulation As Needed May Offer Safe Alternative to Lower Stroke Risk

Presented at Heart Rhythm 2016, new study results show highly motivated patients can effectively monitor their pulse to detect atrial fibrillation after ablation

daily oral anticoagulation therapy, OAT, atrial fibrillation, as needed, HRS 2016 study

May 9, 2016 — A new study shows the use of novel anticoagulants to treat atrial fibrillation (AF) on an “as needed basis” guided by diligent pulse monitoring can be an effective and safe way to lower overall risk of stroke. The study includes motivated patients that were eager to seek an alternative to long-term, daily oral anticoagulation therapy (OAT) after ablation or drug therapy. The research was presented at Heart Rhythm 2016, the Heart Rhythm Society’s 37th Annual Scientific Sessions.

OAT is recommended in patients with infrequent AF and stroke risk (CHA2DS2-VASc) scores that are ≥ 1. However, chronic OAT is associated with a well-defined bleeding risk, which leads patients to be reluctant to take long-term, daily OAT. Patients are especially reluctant when they are able to monitor for AF through manual or device-assisted pulse monitoring. Monitoring one’s pulse via mobile devices like smartphones has become increasingly accessible and accurate over the last several years, offering comprehensive screenings and enabling personalized treatment.[1]

The study enrolled a total of 100 patients aged 45 to 78 with CHA2DS2-VASc scores ≥ 1. Before the study began, all patients had no AF recurrences during an extended period of electrocardiogram monitoring and were willing and able to check their pulses manually or by a smartphone-enabled device (via AliveCor) twice a day. All patients were also considered highly motivated, meaning they were actively seeking, preparing for and committing to this alternate treatment method. Eighty-four percent of patients had been ablated, 16 percent were being treated with drug therapy and three patients had implanted devices that served as a quality control check. All patients were provided with a NOAC — such as rivoraxiban, apixiban and dabigatran — and were instructed to start taking the medication if they suspected or confirmed an AF episode lasting longer than one to two hours.

“This alternative to long-term anticoagulation therapy requires very close and consistent interaction between patient and doctor. It’s imperative that the patients are extremely motivated and informed about how to effectively monitor their pulse throughout the day,” said lead author Monica Pammer, PA-C, a physician assistant at the Hospital of the University of Pennsylvania. “We’re confident that this alternate treatment method is a viable option for low-risk patients who are willing and able to keep a vigilant eye on their pulse and stay closely connected with their doctor if they do experience AF and need to take an anticoagulant.”

During a follow-up of approximately 23 months, 28 patients started taking the blood thinner at least once for suspected or detected AF episode and only 10 patients transitioned back to chronic OAT for recurrent AF episodes. No patients experienced a stroke or transient ischemic attack and there was only one mild bleeding incident (epistaxis) that required medical attention.

“In general, about half of the patients we treat look for alternatives to OAT as they are wary of the increased bleeding risk that comes with taking a blood thinner long-term. We wanted to explore other options and provide them with an effective, safe alternative,” said co-author Francis E. Marchlinski, M.D., FHRS, director of electrophysiology for the University of Pennsylvania Health System and Richard T. and Angela Clark President’s Distinguished Professor in the Perelman School of Medicine at the University of Pennsylvania. “Our study results are encouraging because it’s the first time we’re seeing that an ‘as needed’ approach can work for a specific patient population and provide an alternative to help lower stroke risk and improve overall patient care.”

As this is a pilot study, the authors note that the observational reports should be substantiated by further research in order to better understand alternate treatment options for this particular patient population. The study authors also urge that “as needed” OAT should not be considered an option unless a patient is willing and able to be diligent about twice-daily pulse monitoring.

For more information: www.hrsonline.org

Reference:

1. KONECNY, T. and SAXON, L. A. (2016), Integration of Smartphone Based Monitoring: No Modality is an Island, Entire of Itself. Journal of Cardiovascular Electrophysiology, 27: 58–59. doi: 10.1111/jce.12844

Related Content

common adult CT examinations, computed tomography, diagnostic reference levels, DRLs, radiation dose, achievable dose, AD
News | Radiation Dose Management| February 23, 2017
Using data from the world’s largest computed tomography (CT) dose index registry, researchers have established national...
ACC, Haymarket Medical Education, HME, myCME, RightSTEPS initiative, prescribing behavior, chronic heart failure
News | Heart Failure| February 22, 2017
The American College of Cardiology (ACC), Haymarket Medical Education (HME) and myCME have joined forces to develop...
News | Cardiac Diagnostics| February 17, 2017
Levels of a protein in the blood associated with heart disease are also linked to early-stage brain damage, according...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders| February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Biotronik, ProMRI Configurator tool, MR-conditional cardiac devices, ProMRI SystemCheck
Technology | Implantable Cardiac Monitor (ICM)| February 14, 2017
Biotronik has developed an online tool that streamlines the workflow for physicians selecting the right magnetic...
News | Hypertension| February 13, 2017
Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s...
Xarelto, rivaroxaban, COMPASS study, ends early,
News | Antiplatelet and Anticoagulation Therapies| February 09, 2017
February 9, 2017 — Janssen Research & Development LLC (Janssen) announced that the Phase 3 COMPASS trial is stopp
Medtronic, IDE approval, IN.PACT Admiral drug-coated balloon, DCB, end-stage renal disease
News | Drug-Eluting Balloons| February 08, 2017
Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration...
Overlay Init